Exosomal pHERV-W ENV as a dynamic biomarker for relapse prediction and prognosis in multiple sclerosis
Open Access
- 21 October 2025
- journal article
- research article
- Published by Springer Nature in Journal of Neuroinflammation
- Vol. 22 (1) , 1-14
Abstract
Emerging evidence implicates the envelope protein of human endogenous retrovirus type W (pHERV-W ENV) in the pathogenesis of multiple sclerosis (MS); however, its clinical utility as a biomarker remains incompletely defined. In this study, we demonstrate that pHERV-W ENV is enriched on serum-derived exosomes in patients with relapsing-remitting MS (RRMS), where it reflects both current disease activity and future risk. Exosomal pHERV-W ENV levels were profiled across three cohorts: (1) a cross-sectional cohort including healthy controls, stable MS patients, and patients with active disease; (2) a longitudinal RRMS cohort with samples collected before, during, and after episodes of disease activity; and (3) a retrospective longitudinal cohort of newly diagnosed RRMS patients with three years of follow-up. We observed an increase in exosomal pHERV-W ENV expression during active disease, followed by a decline at follow-up. Levels of pHERV-W ENV expression during active disease positively correlated with Epstein-Barr virus (EBV)-derived latent membrane protein 2 A (LMP2A) expression, supporting an association between endogenous retroviral expression and EBV activity. Flow cytometric profiling of immune cell subsets identified monocytes and B cells as the predominant sources of circulating pHERV-W ENV. Longitudinal profiling further revealed coordinated immune and vascular activation during active disease, including a significant positive correlation between exosomal pHERV-W ENV and the costimulatory molecule CD40. Notably, high baseline levels of exosomal pHERV-W ENV were associated with greater total disease activity events, defined as the sum of clinical relapses and MRI activity (new/enlarging T2 or gadolinium-enhancing (Gd+) lesions) over three years, as well as with accelerated loss of “No Evidence of Disease Activity” (NEDA) status over time. These findings suggest that exosomal pHERV-W ENV expression may serve as a dynamic, non-invasive biomarker of disease activity with prognostic value in MS.Keywords
This publication has 53 references indexed in Scilit:
- The role of serum neurofilament light (sNfL) as a biomarker in multiple sclerosis: insights from a systematic reviewJournal of Neurology, 2025
- Inhibiting CD40 Ligand in Multiple Sclerosis: A Review of Emerging Therapeutic PotentialCurrent Treatment Options in Neurology, 2024
- Human endogenous retrovirus W in multiple sclerosis: transcriptional activity is associated with decline in oligodendrocyte proportions in the white matter of the brainJournal of NeuroVirology, 2024
- Epstein–Barr virus as a leading cause of multiple sclerosis: mechanisms and implicationsNature Reviews Neurology, 2023
- Clonally expanded B cells in multiple sclerosis bind EBV EBNA1 and GlialCAMNature, 2022
- Human Endogenous Retrovirus Type W Envelope from Multiple Sclerosis Demyelinating Lesions Shows Unique Solubility and Antigenic CharacteristicsVirologica Sinica, 2021
- Syncytin‐1/HERV‐W envelope is an early activation marker of leukocytes and is upregulated in multiple sclerosis patientsEuropean Journal of Immunology, 2020
- Transactivation of human endogenous retroviruses by tumor viruses and their functions in virus-associated malignanciesOncogenesis, 2019
- Human Endogenous Retroviruses in Neurological DiseasesTrends in Molecular Medicine, 2018
- Exosomal microRNA signatures in multiple sclerosis reflect disease statusScientific Reports, 2017